O' Connor DP - Search Results

1

Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects.

Miller IS, Khan S, Shiels LP, Das S, O' Farrell AC, Connor K, Lafferty A, Moran B, Isella C, Loadman P, Conroy E, Cohrs S, Schibli R, Kerbel RS, Gallagher WM, Marangoni E, Bennett K, O' Connor DP, Dwyer RM, Byrne AT. Miller IS, et al. Among authors: o connor dp. Cancer Med. 2022 Oct;11(20):3820-3836. doi: 10.1002/cam4.4756. Epub 2022 Apr 17. Cancer Med. 2022. PMID: 35434898 Free PMC article.

2

Surface-induced changes in protein adsorption and implications for cellular phenotypic responses to surface interaction.

Allen LT, Tosetto M, Miller IS, O'Connor DP, Penney SC, Lynch I, Keenan AK, Pennington SR, Dawson KA, Gallagher WM. Allen LT, et al. Biomaterials. 2006 Jun;27(16):3096-108. doi: 10.1016/j.biomaterials.2006.01.019. Epub 2006 Feb 7. Biomaterials. 2006. PMID: 16460797

3

Proteomic analysis of factors released from p21-overexpressing tumour cells.

Currid CA, O'Connor DP, Chang BD, Gebus C, Harris N, Dawson KA, Dunn MJ, Pennington SR, Roninson IB, Gallagher WM. Currid CA, et al. Proteomics. 2006 Jul;6(13):3739-53. doi: 10.1002/pmic.200500787. Proteomics. 2006. PMID: 16739131

4

Molecular basis of cell-biomaterial interaction: insights gained from transcriptomic and proteomic studies.

Gallagher WM, Lynch I, Allen LT, Miller I, Penney SC, O'Connor DP, Pennington S, Keenan AK, Dawson KA. Gallagher WM, et al. Biomaterials. 2006 Dec;27(35):5871-82. doi: 10.1016/j.biomaterials.2006.07.040. Epub 2006 Aug 28. Biomaterials. 2006. PMID: 16938344

5

Breast cancer proteomics: clinical perspectives.

Lau TY, O'Connor DP, Brennan DJ, Duffy MJ, Pennington SR, Gallagher WM. Lau TY, et al. Expert Opin Biol Ther. 2007 Feb;7(2):209-19. doi: 10.1517/14712598.7.2.209. Expert Opin Biol Ther. 2007. PMID: 17250459 Review.

6

Molecular links between mammary gland development and breast cancer.

Lanigan F, O'Connor D, Martin F, Gallagher WM. Lanigan F, et al. Cell Mol Life Sci. 2007 Dec;64(24):3159-84. doi: 10.1007/s00018-007-7386-2. Cell Mol Life Sci. 2007. PMID: 17955178 Review.

7

Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.

Brennan DJ, Rexhepaj E, O'Brien SL, McSherry E, O'Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom K, Millikan RC, Landberg G, Duffy MJ, Hewitt SM, Gallagher WM. Brennan DJ, et al. Clin Cancer Res. 2008 May 1;14(9):2681-9. doi: 10.1158/1078-0432.CCR-07-1760. Clin Cancer Res. 2008. PMID: 18451232 Free PMC article.

8

The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer.

Brennan DJ, Ek S, Doyle E, Drew T, Foley M, Flannelly G, O'Connor DP, Gallagher WM, Kilpinen S, Kallioniemi OP, Jirstrom K, O'Herlihy C, Borrebaeck CA. Brennan DJ, et al. Eur J Cancer. 2009 May;45(8):1510-7. doi: 10.1016/j.ejca.2009.01.028. Epub 2009 Mar 9. Eur J Cancer. 2009. PMID: 19272768

9

Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.

Brennan DJ, Brändstedt J, Rexhepaj E, Foley M, Pontén F, Uhlén M, Gallagher WM, O'Connor DP, O'Herlihy C, Jirstrom K. Brennan DJ, et al. BMC Cancer. 2010 Apr 1;10:125. doi: 10.1186/1471-2407-10-125. BMC Cancer. 2010. PMID: 20359358 Free PMC article.

10

Antibody-based proteomics: fast-tracking molecular diagnostics in oncology.

Brennan DJ, O'Connor DP, Rexhepaj E, Ponten F, Gallagher WM. Brennan DJ, et al. Nat Rev Cancer. 2010 Sep;10(9):605-17. doi: 10.1038/nrc2902. Epub 2010 Aug 19. Nat Rev Cancer. 2010. PMID: 20720569 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241 results

Search Page